Fixed dosing of liposomal Amphotericin B in morbidly obese individuals

Fixed dosing of liposomal Amphotericin B in morbidly obese individuals

AbstractIn this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individuals (104–177 kg). Body size had no effect on clearance. We recommend a fixed dose in patients ≥100 kg (ie, 300 or 500 mg rather than the current dose of 3 and 5...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical Infectious Diseases 2019-10, Vol.70 (10), p.2213-2215
Hauptverfasser: Wasmann, R.E., Smit, C., Dongen, E.P.H. van, Wiezer, R.M.J., Adler-Moore, J., Beer, Y.M. de, Burger, D.M., Knibbe, C.A.J., Bruggemann, R.J.M.
Format: Artikel
Sprache:eng
Schlagworte:
fungal infection
fungal treatment
obese
optimal dosing
population pharmacokinetics
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:AbstractIn this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individuals (104–177 kg). Body size had no effect on clearance. We recommend a fixed dose in patients ≥100 kg (ie, 300 or 500 mg rather than the current dose of 3 and 5 mg/kg, respectively).Clinical Trials Registration NCT02320604.
DOI:10.1093/cid/ciz885